{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:49Z","timestamp":1787013589059,"version":"build-2736575974"},"reference-count":42,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Janus kinase (JAK) inhibitors are emerging treatments for atopic dermatitis (AD). Due to this novel role as a therapeutic option for patients with AD, we aimed to review current evidence on the pathophysiology and the safety and adverse effects (AEs) of oral JAK inhibitors for the treatment of AD utilizing the key terms atopic dermatitis, JAK inhibitors, and adverse effect or event. Our study indicated that oral JAK inhibitors have a moderate safety profile for use in AD in several reviews and phase II or III clinical trials. Headaches, nausea, and nasopharyngitis are the most commonly reported systemic AEs. Furthermore, acne, herpes simplex, herpes zoster, and eczema herpeticum are the most commonly recorded dermatological AEs. Current evidence indicates JAK inhibitors may also have less association with some of the serious AEs, although there is potential for increased risk of asthma, acute pancreatitis, neutropenia, and thrombocytopenia. Whereas data remain limited for the long\u2010term safety of JAK inhibitor use in patients with AD, many ongoing clinical trials have promising preliminary results.<\/jats:p>","DOI":"10.1111\/1346-8138.16116","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T02:31:54Z","timestamp":1630377114000},"page":"1631-1639","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-7786","authenticated-orcid":false,"given":"Po\u2010Hsiung","family":"Chang","sequence":"first","affiliation":[{"name":"School of Medicine Taipei Medical University Taipei City Taiwan"},{"name":"Department of Pediatrics Far Eastern Memorial Hospital New Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng\u2010Fen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Education and Learning Technology National Tsing Hua University Hsinchu Taiwan"},{"name":"Graduate Institute of Medical Education &amp; Bioethics National Taiwan University College of Medicine Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po\u2010Sheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Far Eastern Memorial Hospital New Taipei City Taiwan"},{"name":"Division of Pediatric Gastroenterology Department of Pediatrics Far\u2010Eastern Memorial Hospital New Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-5994","authenticated-orcid":false,"given":"Yu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Cathay General Hospital Taipei City Taiwan"},{"name":"Department of Dermatology Sijhih Cathay General Hospital New Taipei City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000086464"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13231"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.008"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.006"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.003"},{"issue":"587","key":"e_1_2_8_8_1","first-page":"e141","article-title":"A blinded, randomized, placebo\u2010controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client\u2010owned dogs with atopic dermatitis","volume":"24","author":"Cosgrove SB","year":"2013","journal-title":"Vet Dermatol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.004"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8488-5"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12903"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00329-y"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24137"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0413-2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003244"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.018"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17932"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00589-4"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8548-5"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3260"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164080"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S219586"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210911"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000170"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0622-2"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0651-5"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054940"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0419-y"},{"key":"e_1_2_8_38_1","unstructured":"AbbVie.AbbVie\u2019s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis. In: C. I. A. Inc editor.https:\/\/news.abbvie.com\/news\/abbvies\u2010upadacitinib\u2010granted\u2010breakthrough\u2010therapy\u2010designation\u2010from\u2010us\u2010food\u2010and\u2010drug\u2010administration\u2010for\u2010atopic\u2010dermatitis.htm2018."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102750"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","unstructured":"SimpsonEL JisAN WinthropK Guttman\u2010YasskyE HoffmeisterKM ZhangM et al.Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate\u2010to\u2010Severe Atopic Dermatitis From the Phase 2 and Phase 3 Clinical Trial Program. Poster presented at the American Academy of Dermatology 2021 Annual Meeting; April 23\u201025 2021. Virtual.","DOI":"10.1016\/j.jaad.2021.06.615"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","unstructured":"Brett KingCM LainE SilverbergJI IssaM HolzwarthK BrinkerD et al.Extended Safety Analysis of Baricitinib2\u2010mg in Adult Patients With Atopic Dermatitis: An Integrated Analysis From 8 Randomized Clinical Trials. Poster presented at the American Academy of Dermatology 2021 Annual Meeting; April 23\u201025 2021. Virtual.","DOI":"10.1016\/j.jaad.2021.06.525"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T02:58:56Z","timestamp":1745809136000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/1346-8138.16116"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16116","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"2021-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}